WO2015089170A1 - Bicyclic alkyl compounds and synthesis - Google Patents

Bicyclic alkyl compounds and synthesis Download PDF

Info

Publication number
WO2015089170A1
WO2015089170A1 PCT/US2014/069517 US2014069517W WO2015089170A1 WO 2015089170 A1 WO2015089170 A1 WO 2015089170A1 US 2014069517 W US2014069517 W US 2014069517W WO 2015089170 A1 WO2015089170 A1 WO 2015089170A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
compound
unsubstituted
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/069517
Other languages
English (en)
French (fr)
Inventor
Kevin Duane BUNKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalyra Pharmaceuticals Inc
Original Assignee
Kalyra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalyra Pharmaceuticals Inc filed Critical Kalyra Pharmaceuticals Inc
Priority to CN201480067673.7A priority Critical patent/CN105814013A/zh
Priority to US15/103,038 priority patent/US10189780B2/en
Priority to EP14869147.0A priority patent/EP3080072A4/en
Priority to KR1020167016840A priority patent/KR102380609B1/ko
Priority to CA2932039A priority patent/CA2932039A1/en
Priority to JP2016558533A priority patent/JP6542794B2/ja
Publication of WO2015089170A1 publication Critical patent/WO2015089170A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06Halogens; Compounds thereof
    • B01J27/128Halogens; Compounds thereof with iron group metals or platinum group metals
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/04Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • B01J31/2204Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208Oxygen, e.g. acetylacetonates
    • B01J31/2217At least one oxygen and one nitrogen atom present as complexing atoms in an at least bidentate or bridging ligand
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
    • B01J31/28Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/013Preparation of halogenated hydrocarbons by addition of halogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/093Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/10Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C207/00Compounds containing nitroso groups bound to a carbon skeleton
    • C07C207/02Compounds containing nitroso groups bound to a carbon skeleton the carbon skeleton not being further substituted
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/30Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
    • C07C209/42Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitrogen-to-nitrogen bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C23/00Compounds containing at least one halogen atom bound to a ring other than a six-membered aromatic ring
    • C07C23/18Polycyclic halogenated hydrocarbons
    • C07C23/20Polycyclic halogenated hydrocarbons with condensed rings none of which is aromatic
    • C07C23/24Polycyclic halogenated hydrocarbons with condensed rings none of which is aromatic with a bicyclo ring system containing five carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00Compounds containing azido groups
    • C07C247/14Compounds containing azido groups with azido groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/12Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reactions not involving the formation of oxyimino groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/42Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/45Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/62Carboxylic acid nitriles containing cyano groups and oxygen atoms being part of oxyimino groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/63Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C255/64Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C263/00Preparation of derivatives of isocyanic acid
    • C07C263/16Preparation of derivatives of isocyanic acid by reactions not involving the formation of isocyanate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00Derivatives of isocyanic acid
    • C07C265/10Derivatives of isocyanic acid having isocyanate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/48Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups
    • C07C29/50Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups with molecular oxygen only
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02Thiocyanates
    • C07C331/06Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/23Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
    • C07C35/24Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system containing five carbon atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/48Ring-opening reactions
    • B01J2231/482Ring-opening reactions asymmetric reactions, e.g. kinetic resolution of racemates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/001General concepts, e.g. reviews, relating to catalyst systems and methods of making them, the concept being defined by a common material or method/theory
    • B01J2531/002Materials
    • B01J2531/007Promoter-type Additives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/845Cobalt
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms

Definitions

  • the present disclosure relates to synthetic organic chemistry, and in particular to [l .l . l]-bicyclopentane-based compounds (propellane derivatives) and their synthesis.
  • BCP bicyclo[l . l .l]pentane
  • BCP has been the subject of some experimentation as a structural motif in pharmaceuticals, polymers, liquid crystal displays, high energy density materials, nanoparticles or molecular rods, macrocycles, organometallic complexes, and physical organic chemistry
  • compounds having a BCP structure have yet to be commercialized in those fields.
  • commercial use of BCPs has been hampered by availability and cost of reagents.
  • Some embodiments disclosed herein relate to a method for preparing a substituted bicyclo[l . l .l]pentane compound that can include combining [l .l . ljpropellane; a Group VII transition metal compound or a Group IX transition metal compound; a hydride source; and a reagent capable of contributing all or a part of a substituent group such that bicyclo[l .l .l]pentane is substituted with the substituent group.
  • Some embodiments described herein relate to using a method described herein to obtain a compound of Formula (I).
  • Bicyclo[l .l .l]pentanes are remarkably stable, despite being highly ring- strained.
  • the first example of an isolated bicyclo[l .l . l]pentane was reported by Wiberg in 1964 (Wiberg et al. Tetrahedron Lett. 1964, 531-4).
  • development of the bicyclo[l . l .l]pentane field was slow due to the difficult and low yielding chemistry.
  • Some twenty years passed before a more productive route into BCPs was discovered by Wiberg (Wiberg et al. J Am. Chem. Soc. 1982, 104, 5239-40) and further developed by Sziemes (Semmler et al. J Am. Chem. Soc. 1985, 107, 6410-11) that utilized the highly ring-strained [1.1.1 jpropellane as a starting material.
  • Bicyclo[l .l .l]pentane has unique properties, including shape (sterics) and polarity (electronics) where the high ring-strain creates an electron withdrawing effect for substituents on the bridgehead carbons.
  • shape stereos
  • polarity electrospentyl
  • l-bicyclo[l .l .l]pentyl amine is significantly less basic compared to tert-butylamine (pKa of the conjugate acid is 8.6 for 1- bicyclo[l .l .l]pentyl amine vs. 11.0 for tBuNH 2 ).
  • l-carboxybicyclo[l .l .l]pentane is more acidic than pivalic acid (pKa of 4.09 for l-carboxybicyclo[l .l . l]pentanes vs. 5.05 for pivalic acid).
  • the indicated “optionally substituted” or “substituted” group may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), (heterocyclyl)alkyl, hydroxy, alkoxy, acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, sul
  • C a to Ct in which "a” and “b” are integers refer to the number of carbon atoms in a group.
  • the indicated group can contain from “a” to "b", inclusive, carbon atoms.
  • a "Ci to C 4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH 3 -, CH 3 CH 2 -, CH 3 CH 2 CH 2 -, (CH 3 ) 2 CH-, CH 3 CH 2 CH 2 CH 2 -, CH 3 CH 2 CH(CH 3 )- and (CH 3 ) 3 C-. If no "a” and "b” are designated, the broadest range described in these definitions is to be assumed.
  • alkyl refers to a fully saturated aliphatic hydrocarbon group.
  • the alkyl moiety may be branched or straight chain.
  • branched alkyl groups include, but are not limited to, iso-propyl, sec-butyl, t-butyl and the like.
  • straight chain alkyl groups include, but are not limited to, methyl, ethyl, n- propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and the like.
  • the alkyl group may have 1 to 30 carbon atoms (whenever it appears herein, a numerical range such as “1 to 30" refers to each integer in the given range; e.g., "1 to 30 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 30 carbon atoms, although the present definition also covers the occurrence of the term "alkyl” where no numerical range is designated).
  • the alkyl group may also be a medium size alkyl having 1 to 12 carbon atoms.
  • the alkyl group could also be a lower alkyl having 1 to 6 carbon atoms.
  • An alkyl group may be substituted or unsubstituted.
  • alkenyl refers to a monovalent straight or branched chain radical of from two to twenty carbon atoms containing a carbon double bond(s) including, but not limited to, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl, and the like.
  • An alkenyl group may be unsubstituted or substituted.
  • alkynyl refers to a monovalent straight or branched chain radical of from two to twenty carbon atoms containing a carbon triple bond(s) including, but not limited to, 1-propynyl, 1-butynyl, 2-butynyl, and the like.
  • An alkynyl group may be unsubstituted or substituted.
  • cycloalkyl refers to a completely saturated (no double or triple bonds) mono- or multi- cyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro fashion. Cycloalkyl groups can contain 3 to 10 atoms in the ring(s) or 3 to 8 atoms in the ring(s). A cycloalkyl group may be unsubstituted or substituted.
  • Typical cycloalkyl groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • cycloalkenyl refers to a mono- or multi- cyclic hydrocarbon ring system that contains one or more double bonds in at least one ring; although, if there is more than one, the double bonds cannot form a fully delocalized pi- electron system throughout all the rings (otherwise the group would be "aryl,” as defined herein).
  • Cycloalkenyl groups can contain 3 to 10 atoms in the ring(s) or 3 to 8 atoms in the ring(s). When composed of two or more rings, the rings may be connected together in a fused, bridged or spiro fashion. A cycloalkenyl group may be unsubstituted or substituted.
  • cycloalkynyl refers to a mono- or multi- cyclic hydrocarbon ring system that contains one or more triple bonds in at least one ring. If there is more than one triple bond, the triple bonds cannot form a fully delocalized pi-electron system throughout all the rings.
  • Cycloalkynyl groups can contain 3 to 10 atoms in the ring(s) or 3 to 8 atoms in the ring(s). When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro fashion.
  • a cycloalkynyl group may be unsubstituted or substituted.
  • alkoxy refers to the formula -OR wherein R is an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl.
  • R is an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl.
  • alkoxys are methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, phenoxy and benzoxy.
  • An alkoxy may be
  • aryl refers to a carbocyclic (all carbon) monocyclic or multicyclic aromatic ring system (including fused ring systems where two carbocyclic rings share a chemical bond) that has a fully delocalized pi-electron system throughout all the rings.
  • the number of carbon atoms in an aryl group can vary.
  • the aryl group can be a C6-C 14 aryl group, a C 6 -Cio aryl group, or a C 6 aryl group.
  • Examples of aryl groups include, but are not limited to, benzene, naphthalene and azulene.
  • An aryl group may be substituted or unsubstituted.
  • heteroaryl refers to a monocyclic or multicyclic aromatic ring system (a ring system with fully delocalized pi-electron system) that contain(s) one or more heteroatoms (for example, 1, 2 or 3 heteroatoms), that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur.
  • the number of atoms in the ring(s) of a heteroaryl group can vary.
  • the heteroaryl group can contain 4 to 14 atoms in the ring(s), 5 to 10 atoms in the ring(s) or 5 to 6 atoms in the ring(s).
  • heteroaryl includes fused ring systems where two rings, such as at least one aryl ring and at least one heteroaryl ring, or at least two heteroaryl rings, share at least one chemical bond.
  • heteroaryl rings include, but are not limited to, furan, furazan, thiophene, benzothiophene, phthalazine, pyrrole, oxazole, benzoxazole, 1,2,3-oxadiazole, 1,2,4- oxadiazole, thiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, benzothiazole, imidazole, benzimidazole, indole, indazole, pyrazole, benzopyrazole, isoxazole, benzoisoxazole, isothiazole, triazole, benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine, pyrim
  • heterocyclyl or “heteroalicyclyl” refers to three-, four-, five-, six-, seven-, eight-, nine-, ten-, up to 18-membered monocyclic, bicyclic, and tricyclic ring system wherein carbon atoms together with from 1 to 5 heteroatoms constitute said ring system.
  • a heterocycle may optionally contain one or more unsaturated bonds situated in such a way, however, that a fully delocalized pi-electron system does not occur throughout all the rings.
  • the heteroatom(s) is an element other than carbon including, but not limited to, oxygen, sulfur, and nitrogen.
  • a heterocycle may further contain one or more carbonyl or thiocarbonyl functionalities, so as to make the definition include oxo-systems and thio- systems such as lactams, lactones, cyclic imides, cyclic thioimides and cyclic carbamates. When composed of two or more rings, the rings may be joined together in a fused or spiro fashion. Additionally, any nitrogens in a heteroalicyclic may be quaternized. Heterocyclyl or heteroalicyclic groups may be unsubstituted or substituted.
  • heterocyclyl or “heteroalicyclyl” groups include but are not limited to, 1,3-dioxin, 1,3-dioxane, 1,4- dioxane, 1 ,2-dioxolane, 1,3-dioxolane, 1 ,4-dioxolane, 1,3-oxathiane, 1 ,4-oxathiin, 1,3- oxathiolane, 1,3-dithiole, 1,3-dithiolane, 1 ,4-oxathiane, tetrahydro-l,4-thiazine, 2H-1,2- oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, trioxane, hexahydro-l,3,5-triazine, imidazoline, imidazolidine,
  • aralkyl and aryl(alkyl) refer to an aryl group connected, as a substituent, via a lower alkylene group.
  • the lower alkylene and aryl group of an aralkyl may be substituted or unsubstituted. Examples include but are not limited to benzyl, 2-phenyl(alkyl), 3-phenyl(alkyl), and naphthyl(alkyl).
  • heteroarylkyl and “heteroaryl(alkyl)” refer to a heteroaryl group connected, as a substituent, via a lower alkylene group.
  • the lower alkylene and heteroaryl group of heteroaralkyl may be substituted or unsubstituted. Examples include but are not limited to 2-thienyl(alkyl), 3-thienyl(alkyl), furyl(alkyl), thienyl(alkyl), pyrrolyl(alkyl), pyridyl(alkyl), isoxazolyl(alkyl), imidazolyl(alkyl), and their benzo-fused analogs.
  • heteroalicyclyl(alkyl) and “heterocyclyl(alkyl)” refer to a heterocyclic or a heteroalicyclic group connected, as a substituent, via a lower alkylene group.
  • the lower alkylene and heterocyclyl of a (heteroalicyclyl)alkyl may be substituted or unsubstituted. Examples include but are not limited tetrahydro-2H-pyran-4-yl(methyl), piperidin-4-yl(ethyl), piperidin-4-yl(propyl), tetrahydro-2H-thiopyran-4-yl(methyl), and 1, 3 -thiazinan-4-yl (methyl).
  • Lower alkylene groups are straight-chained -CH 2 - tethering groups, forming bonds to connect molecular fragments via their terminal carbon atoms. Examples include but are not limited to methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene (- CH 2 CH 2 CH 2 -), and butylene (-CH 2 CH 2 CH 2 CH 2 -).
  • a lower alkylene group can be substituted by replacing one or more hydrogen of the lower alkylene group and/or by substituting both hydrogens on the same carbon with a cycloalkyl group (e.g., ⁇ C- ).
  • acyl refers to a hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl) and heterocyclyl(alkyl) connected, as substituents, via a carbonyl group. Examples include formyl, acetyl, propanoyl, benzoyl, and acryl. An acyl may be substituted or unsubstituted.
  • amino used herein refers -NH 2 .
  • a "mono-substituted amino” group refers to a "-NHR" group in which R can be an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl), as defined herein.
  • a mono-substituted amino may be substituted or unsubstituted. Examples of mono-substituted amino groups include, but are not limited to, -NH(methyl), -NH(phenyl) and the like.
  • a "di-substituted amino” group refers to a "-NRARB" group in which R A and R B can be independently an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl), as defined herein.
  • a di-substituted amino may be substituted or unsubstituted. Examples of di-substituted amino groups include, but are not limited to, -N(methyl) 2 , -N(phenyl)(methyl), -N(ethyl)(methyl) and the like.
  • halogen atom or "halogen” as used herein, means any one of the radio-stable atoms of column 7 of the Periodic Table of the Elements, such as, fluorine, chlorine, bromine and iodine.
  • haloalkyl refers to an alkyl group in which one or more of the hydrogen atoms are replaced by a halogen (e.g., mono-haloalkyl, di-haloalkyl and tri- haloalkyl).
  • a halogen e.g., mono-haloalkyl, di-haloalkyl and tri- haloalkyl.
  • groups include but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl and 1 -chloro-2-fluoromethyl, 2-fluoroisobutyl.
  • a haloalkyl may be substituted or unsubstituted.
  • hydroxyalkyl refers to an alkyl group in which one or more of the hydrogen atoms are replaced by a hydroxy group.
  • exemplary hydroxyalkyl groups include but are not limited to, 2-hydroxy ethyl, 3-hydroxypropyl, 2-hydroxypropyl, and 2,2-dihydroxyethyl.
  • a hydroxyalkyl may be substituted or unsubstituted.
  • alkoxyalkyl refers to an alkoxy group connected, as a substituent, via a lower alkylene group. Examples include alkyl-0-(CH 2 )n- ,wherein n is an integer in the range of 1 to 6.
  • aminoalkyl refers to an optionally substituted amino group connected, as a substituent, via a lower alkylene group. Examples include H 2 N- (CH 2 )n-, (CH 3 ) 2 N-(CH 2 )n- and (CH 3 )(phenyl)N-(CH 2 )n-,wherein n is an integer in the range of 1 to 6.
  • haloalkoxy refers to an -O-alkyl group in which one or more of the hydrogen atoms are replaced by a halogen (e.g., mono-haloalkoxy, di- haloalkoxy and tri- haloalkoxy).
  • a halogen e.g., mono-haloalkoxy, di- haloalkoxy and tri- haloalkoxy.
  • groups include but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 1 -chloro-2-fluoromethoxy and 2- fluoroisobutoxy.
  • a haloalkoxy may be substituted or unsubstituted.
  • a “sulfonyl” group refers to an “S0 2 R” group in which R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl.
  • R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl.
  • a sulfenyl may be substituted or unsubstituted.
  • substituents there may be one or more substituents present.
  • haloalkyl may include one or more of the same or different halogens.
  • Ci-C 3 alkoxyphenyl may include one or more of the same or different alkoxy groups containing one, two or three atoms.
  • a radical indicates species with a single, unpaired electron such that the species containing the radical can be covalently bonded to another species.
  • a radical is not necessarily a free radical. Rather, a radical indicates a specific portion of a larger molecule.
  • the term "radical” can be used interchangeably with the term "group.”
  • each center may independently be of R-configuration or S -configuration or a mixture thereof.
  • the compounds provided herein may be enantiomerically pure, enantiomerically enriched, racemic mixture, diastereomerically pure, diastereomerically enriched, or a stereoisomeric mixture.
  • each double bond may independently be E or Z a mixture thereof.
  • valencies are to be filled with hydrogens or isotopes thereof, e.g., hydrogen- 1 (protium) and hydrogen-2 (deuterium).
  • Some embodiments disclosed herein relate to a method for preparing a substituted bicyclo[l .l .l]pentane compound that can include combining [l .l .ljpropellane; a Group VII transition metal compound or a Group IX transition metal compound; a hydride source; and a reagent capable of contributing all or a part of a substituent group such that bicyclo[l . l .l]pentane is substituted with the substituent group.
  • the hydride source contributes the shown hydrogen and the reagent contributes R 1 or a portion of R 1 to the substituted bicyclo[l .l .l]pentane compound.
  • various Group VII compounds, Group IX compounds, reagents that include R 1 or a portion of R 1 and hydride sources can be used to form a substituted bicyclo[l .l . l]pentane compound.
  • [l .l .l]Propellane can be prepared via various methods. Suitable methods are described by Shtarev et al., J Am. Chem. Soc. 2001, 123, 3484-3492 and Lynch et al., Org. Synth. 1998, 75, 98-105, which are hereby incorporated by reference in their entireties. One example of a suitable method is shown in Scheme 2.
  • Group VII includes the following elements: cobalt, rhodium, iridium and meitnerium; and Group IX includes manganese, technetium, rhenium and bohrium.
  • the Group VII transition metal compound can be a cobalt-based transition metal compound.
  • the oxidation state of the transition metal compound can vary.
  • the oxidation state of cobalt can be Co(II), such that the Group VII transition metal compound is a Co(II)-based transition metal compound.
  • the oxidation state of cobalt can be Co(III), such that the Group VII transition metal compound is a Co(III)-based transition metal compound.
  • the Group IX transition metal compound can be a manganese-based compound.
  • the oxidation state of the manganese of the manganese-based transition metal compound can vary.
  • the oxidation state of manganese can be Mn(II), such that the Group IX transition metal compound is a Mn(II)-based transition metal compound.
  • the oxidation state of manganese can be Mn(III), such that the Group IX transition metal compound is a Mn(III)- based transition metal compound.
  • the Group VII and Group IX transition metal compound can be a salt, a solvate (including mono- and per-solvates) or a hydrate (including mono- and per-hydrates).
  • the Group VII transition metal compound can include one or more ligands attached and/or coordinated to the Group VII metal, such that the Group VII transition metal compound is a Group VII transition metal complex.
  • the Group IX transition metal compound can include one or more ligands attached and/or coordinated to the Group IX metal, such that the Group IX transition metal compound is a Group IX transition metal complex.
  • the term "ligand" is used herein in its ordinary sense as understood by those skilled in the art, and refers to a group bound to a central atom in a chelate or a coordination compound.
  • Suitable ligands include Schiff-based ligands (such as salen-type ligands), 2-(3,5-di-tert-butyl-2- hydroxybenzylideneamino)-2,2-diphenylacetate, salicylaldehyde together with 2- aminoisobutyric acid and salicylaldehyde together with alanine. Additional examples of suitable ligands are provided below:
  • more than one ligand can be present in the Group VII transition metal complex. In some embodiments, more than one ligand may be present in the Group IX transition metal complex. In some embodiments, the Group VII transition metal complex can be a cobalt-based transition metal complex. In some embodiments, the Group IX transition metal complex can be a manganese-based transition metal complex.
  • the amount of the Group VII transition metal compound or the Group IX transition metal compound used in a method described herein can vary. In some embodiments, the Group VII transition metal compound or the Group IX transition metal compound can be present in a stoichiometric amount. In other embodiments, the Group VII transition metal compound or the Group IX transition metal compound can be present in a catalytic amount. In still other embodiments, the Group VII transition metal compound or the Group IX transition metal compound can be present in an excess amount.
  • Group VII and Group IX transition metal compounds include the following: tris(2,2,6,6-tetramethyl-3,5-heptanedionato) manganese(III) [Mn(dpm) 3 ], (acetato-KO)[[rel- ( 1 R,2R)-2,2'- [ 1 ,2-cyclohexanediylbis [(nitrilo-KN)methylidyne] ]bis [4,6-bis( 1,1- dimethylethyl)phenolato-KO]](2-)]cobalt(III), and [N,N'-(l,l,2,2-tetramethylethylene)bis(3,5- di-tert-butylsalicylideneiminato)]cobalt(II).
  • Additional examples include, but are not limited to, cobalt(II) nitrate, cobalt(II) acetate, cobalt(II) chloride, cobalt(II) tetrafluoroborate, bis(2,4-pentanedionato)cobalt (Co(acac) 2 , bis(2,2,6,6-tetramethyl-3,5-heptanedionato) cobalt(II), bis(l-morpholinocarbamoyl-4,4-dimethyl-l,3-pentanedio-nato)cobalt(II) (Co(modp) 2 ), manganese(II) acetate, and the like.
  • transition metal compounds include the following:
  • L can be a coordinating solvent (for example, water, methanol, ethanol, THF, acetone, and the like).
  • the Group VII transition metal compound can be er embodiments, the Group VII transition
  • meta l compound can be
  • the Group VII and Group IX transition metal compounds are commercially available and/or can be prepared using methods known to those skilled in the art. Examples are provided in the following: Gaspar et al., Angew. Chem., Int. Ed. 2007, 46, 4519-4522; Gaspar et al, Angew. Chem., Int. Ed. 2008, 47, 5758-5760; Schaus et al, J Am. Chem. Soc., 2002, 124, 1307-1315; European Patent Publication EP1323725, published July 2, 2003; Waser et al., J. Am. Chem. Soc. 2006, 128, 1 1693-11712; and Gaspar et al, Am. Chem. Soc. 2009, 131, 13214-13215, which are hereby incorporated by reference in their entireties.
  • reagents can be used to contribute all or a part of a substituent group to the bicyclo[l . l .l]pentane compound.
  • the reagent can function as an electrophile and can trap a nucleophile.
  • the reagent can function as a radical trap of a carbon radical species to provide the substituted BCP.
  • the reagent capable of contributing all or a part of a substituent group can have the structure LG ⁇ R 1 , wherein R 1 attaches to a carbon of [l .l .l]propellane and LG 1 is a leaving group.
  • leaving group refers to any atom or moiety that is capable of being displaced by another atom or moiety in a chemical reaction. More specifically, in some embodiments, “leaving group” refers to the atom or moiety that is displaced in a nucleophilic substitution reaction. In some embodiments, “leaving groups” are any atoms or moieties that are conjugate bases of strong acids. Examples of suitable leaving groups include, but are not limited to, tosylates, mesylates, sulfonyls, and halogens (e.g., I, Br, and CI).
  • Non-limiting characteristics and examples of leaving groups can be found, for example in Organic Chemistry, 2 nd ed., Francis Carey (1992), pages 328-331 ; Introduction to Organic Chemistry, 2 nd ed., Andrew Streitwieser and Clayton Heathcock (1981), pages 169- 171 ; and Organic Chemistry, 5 th ed., John McMurry (2000), pages 398 and 408; all of which are incorporated herein by reference for the limited purpose of disclosing characteristics and examples of leaving groups.
  • LG 1 can be an optionally substituted sulfonyl, an optionally substituted phosphonate, an alkali metal or a transition metal.
  • Various of optionally substituted sulfonyls and optionally substituted phosphonate are suitable.
  • the optionally substituted sulfonyl can be an optionally substituted tosyl.
  • the optionally substituted phosphonate can be an optionally substituted di(alkyl)cyanophosphonate (for example, di(ethyl)cyanophosphonate).
  • a non-limiting list of examples of the reagents having the structure LG 1 - R 1 include tosyl azide, sulfonyl azide, lithium azide, sodium azide, potassium azide, cesium azide, zinc azide, tosyl cyanide, tosyl chloride, potassium thiocyanate, potassium cyanate, sodium nitrite, (E)-(phenylsulfonyl)methanal O-benzyl oxime, (E)-N-(benzyloxy)-l- (phenylsulfonyl)methanimidoyl cyanide, diethyl phosphorocyanidate, tert-butylisocyanate, and an optionally substituted sulfonyl oxime.
  • the reagent capable of contributing all or a part of a substituent group can have the structure R 1A -R 1B , wherein R 1B attaches to a carbon of [l .l .l]propellane and undergoes a further transformation to form R 1 , and R 1A forms a byproduct.
  • R 1A -R 1B is molecular oxygen.
  • One oxygen atom of molecular oxygen attached to a carbon of [l .l .l]propellane and the other oxygen forms an oxide byproduct (e.g., silanoxy byproduct).
  • a further example of a reagent capable of contributing all or a part of a substituent group having the structure R 1A -R 1 B is an optionally substituted oxaziridine.
  • the reagent capable of contributing all or a part of a substituent group can have the structure R 1 .
  • all the atoms of the reagent can add to a carbon of [l . l .ljpropellane to form the substituted BCP.
  • An example of this type of reagent is 2,2,6, 6-tetramethyl-l-piperidinyloxy (TEMPO).
  • the reagent capable of contributing all or a part of a substituent group can have the structure of an optionally substituted R' -C2-io alkenyl.
  • R ⁇ -Ca-io alkenyl can be unsubstituted.
  • R ⁇ -Ci-io alkenyl can be substituted.
  • the reagent capable of contributing all or a part of a substituent group can have the structure of an optionally substituted R l -C2-e alkenyl
  • hydride source is a reagent capable of donating a H " or H-radical ( ⁇ ). Suitable hydride sources can transfer a hydride to [l .l .ljpropellane or the metal center of the Group VII or IX transition metal compound to give a metal-hydride complex.
  • the hydride source can be a metal-based hydride source.
  • examples include, but are not limited to, alkali metal-based hydrides, and alkali metal-based borohydrides (such as, sodium borohydride, sodium cyanoborohydride, lithium borohydride and sodium triacetoxyborohydride).
  • the hydride source can be a non-metal-based hydride source.
  • non-metal-based hydride sources include, but are not limited to, silanes (for example, phenylsilane and methyldiphenylsilane), 1,1,3,3-tetramethyldisiloxane (TMDSO) and an optionally substituted borane (such as, BH 3 , BH 3 -complex, 9-Borabicyclo[3.3.1]nonane (9-BBN), and isopinocampheylborane).
  • silanes for example, phenylsilane and methyldiphenylsilane
  • TMDSO 1,1,3,3-tetramethyldisiloxane
  • an optionally substituted borane such as, BH 3 , BH 3 -complex, 9-Borabicyclo[3.3.1]nonane (9-BBN), and isopinocampheylborane.
  • Hydride source reagents can be obtained from commercial vendors and/or prepared utilizing methods known to those skilled in the art.
  • the deuterated equivalents can also be obtained from commercial vendors and/or prepared using commercially available reagents, for example, as described in Keinan et al., J Org. Chem., 1987, 52, 2576-2580 and Harvey et al., J Am. Chem. Soc, 1957, 79, 1437-1439. which are hereby incorporated by reference in their entireties.
  • a method provided herein can include adding a first portion of a hydride source and a second portion of a hydride source.
  • the amounts of [l . l .ljpropellane, the Group VII or Group IX transition metal compound, the hydride source and the reagent capable of contributing all or a part of a substituent group can vary. In some embodiments, one or more of the [l . l .ljpropellane, the Group VII or Group IX transition metal compound, the hydride source and the reagent capable of contributing all or a part of a substituent group can be in excess to another one or more of the aforementioned compounds. In some embodiments, the reagent capable of contributing all or a part of a substituent group can be in excess of [l .l . ljpropellane and/or the hydride source.
  • the hydride source can be in excess of [l .l . ljpropellane and/or the reagent capable of contributing all or a part of a substituent group.
  • [l .l .ljpropellane can be in excess of the hydride source and/or the reagent capable of contributing all or a part of a substituent group.
  • the amount in excess can vary. For example, the amount in excess can be about 1.2 times or more, about 1.5 times or more, about 2 times or more, about 3 times or more, or about 4 times or more.
  • one or more of [l .l .ljpropellane, the Group VII or Group IX transition metal compound, the hydride source and the reagent capable of contributing all or a part of a substituent group can be in approximately equal molar amounts to another one or more of the aforementioned compounds.
  • each of [l .l .ljpropellane, the Group VII or Group IX transition metal compound, the hydride source and the reagent capable of contributing all or a part of a substituent group are combined can also vary.
  • the Group VII or Group IX transition metal compound can be combined with the reagent capable of contributing all or a part of a substituent group, followed by the addition of [l .l .ljpropellane and the hydride source.
  • [l .l . ljpropellane can be added before the reagent capable of contributing all or a part of a substituent group.
  • a method described herein can include one or more additional compounds.
  • a method described herein can also include an additional compound that can act as an initiator.
  • An initiator can generate a reactive radical species to facilitate the reaction.
  • a method described herein can also include a compound that can act as a trapping compound.
  • a trapping compound can combine with a byproduct of one of the compounds formed in a method described herein and can reduce the number of side reaction(s) and/or the amount of side products formed during the reaction.
  • the trapping compound can be a radical trapping compound.
  • An example of a radical trapping compound is butylated hydroxytoluene (BHT).
  • a method described herein can also include an additional compound that can act as an additive.
  • an "additive" facilitates the regeneration of a reactive compound.
  • an additive can regenerate the reactive transition metal compound.
  • Suitable additional compounds that can be used in a methods descried herein include, for example, tert-butyl hydroperoxide, benzoyl peroxide, di-tert- butyl peroxide, 2,2'-azobis(2-methylpropionitrile) (AIBN), methylmorpholine oxide, potassium hexacyanoferrate(III), oxygen, sodium periodate, silver bromoate, silver chloroformate, eerie ammonium nitrate, hydrogen peroxide, sodium hypochlorite, Oxone®, 3-chloroperbenzoic acid, and the like.
  • One or more additional compounds can be included in a method provided herein at various points. Likewise, various amounts of one or more additional compounds can be included in a method provided herein. The timing and amounts of additional compounds to include in a methods provided herein is within the knowledge of those skilled in the art.
  • the solvent can be an alcohol-based solvent.
  • a co-solvent can be used in a method described herein. Suitable solvents and co-solvents include, but are not limited to, ethanol, methanol, isopropanol, H 2 0, THF, Et 2 0, NMP, DMF, DMSO, MTBE, CH 3 CN, CH 2 CI 2 , toluene, or dioxane, and mixtures thereof.
  • the solvent can be H 2 0.
  • the solvent can be THF.
  • the solvent and co-solvent combination can be H 2 0 and THF.
  • the solvent can be isopropanol.
  • the solvent can be a solvent system of methanol and Et 2 0. Time and Temperature
  • the methods provided herein can be conducted at various temperatures. Further, the temperature can be lowered and/or raised during the method. In some embodiments, the temperature can be in the range of about -5 °C to about 30 °C. In some embodiments, the temperature can be room temperature (about 25 °C). In other embodiments, the temperature can be about 0 °C. In some embodiments, the temperature can be greater 30 °C. In other embodiments, the temperature can be less than 0 °C.
  • the time can also vary for a method described herein.
  • the time of a method provided herein can be in the range of about 30 minutes to about 3 hours. In some embodiments, the time can be in the range of about 10 hours to about 24 hours.
  • the R 1 that is first attached to the BCP can undergo further transformations to form other R 1 groups.
  • an R 1 group can be reduced using methods known to those skilled in the art to form other R 1 groups.
  • further transformations include reduction, oxidation, addition, elimination, condensation, coupling, metathesis, rearrangements, cyclizations, aromatization, annulations, fragmentations, substitutions, transfers, homologations, and multicomponent reactions.
  • an azide can be reduced using methods known to those skilled in the art to form an amino group.
  • suitable transformations are provided in Richard C. Larock Comprehensive Organic Transformations: A Guide to Functional Group Preparations (2 nd Ed., Wiley, John & Sons, Inc., Nov. 1999); and Jerry March, ⁇ Advanced Organic Chemistry: Reactions, Mechanisms, and Structure (6 th Ed., Wiley, John & Sons, Inc., Jan. 2007).
  • R" can be (Ci to Cio) alkoxy, substituted or unsubstituted (Ci to C 30 ) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocycle, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl(alkyl), substituted or unsubstituted alkyl(aryl), or substituted or unsubstituted heteroaryl(alkyl).
  • R 1 can be CF 3 , F, CI, Br, I, CN, OH or NCO.
  • R 1 can be N 3 .
  • R 1 can be CF 3 .
  • R 1 can be F.
  • R 1 can be CI.
  • R 1 can be Br.
  • R 1 can be I.
  • R 1 can be CN.
  • R 1 can be OH.
  • R 1 can be SCN.
  • R 1 can be NCO.
  • R 1 can be NO.
  • R 2 can be a variety of groups.
  • R 2 can be
  • R can be an optionally substituted benzyl.
  • OR can be carbimidoyl cyanide, carbaldehyde oxime, (benzyloxy) carbimidoyl cyanide or carbaldehyde O-benzyl oxime.
  • a solution of catalyst A or B (2-5 mol %) was dissolved in either a 3 : 1 or 2: 1 mixture of anhydrous MeOH and anhydrous Et 2 0 containing 1 ppm BHT (10 mM final concentration) and stirred under N 2 for 2 mins.
  • Propellane (1 eq.) and the appropriate trapping agent (1.2 - 1.5 eq.) were added followed by PhSiH 3 (1.0 eq.). After stirring overnight at RT (room temperature), the mixture was concentrated to afford the desired compound that was either further purified by flash chromatography on silica gel or used without further purification.
  • Catalyst A Catalyst B
  • N-(benzyloxy)bicyclo[l .l .l]pentane-l-carbimidoyl cyanide was prepared according to the general procedure of Example 1 using N-(benzyloxy)-l- (methylsulfonyl)methanimidoyl cyanide, catalyst A and phenylsilane in MeOH/Et 2 0. The product was isolated as a mixture of isomers (E and Z). Major isomer: 1H NMR (400 MHz, MeOH-d4) ⁇ 7.37 - 7.33 (m, 5H), 5.24 (s, 2H, 2.53 (s, 1H), 2.07 (s, 6H).
  • N-(benzyloxy)bicyclo[l .l . l]pentane-l-carbimidoyl cyanide was prepared according to the general procedure of Example 1 using tosylmethanal O-benzyl oxime, catalyst A and phenylsilane in MeOH/Et 2 0.
  • l-azidobicyclo[l .l .l]pentane was prepared according to the general procedure of Example 1 using tosyl azide, catalyst B and phenysilane in MeOH/Et 2 0.
  • l-aminobicyclo[l . l .l]pentane is formed from l-azidobicyclo[l .l .l]pentane using the conditions described herein. (See Goh, Y. L., et al., Organic Letters 2014, 16(7), 1884-1887). Therefore, obtaining 1- aminobicyclo[l .l .l]pentane from the conditions described herein is evidence of the formation of l-azidobicyclo[l .l . l]pentane from BCP using tosyl azide, catalyst B and phenysilane in MeOH/Et 2 0.
  • Example 6 The general procedure of Example 6 is repeated using oxygen as an addition reagent, and to produce bicyclo[l .l .l]pentan-l-ol. Alternatively, the general procedure of Example 1 is followed using the appropriate reagents.
  • Example 6 The general procedure of Example 6 is repeated using potassium thiocyanate as an addition reagent, producing l-thiocyanatobicyclo[ 1.1.1 Jpentane. Alternatively, the general procedure of Example 1 is followed using the appropriate reagents.
  • Example 6 The general procedure of Example 6 is repeated using potassium cyanate as addition reagent, to produce l-isocyanatobicyclo[l .l .l]pentane.
  • Example 1 the general procedure of Example 1 is followed using the appropriate reagents.
  • Example 6 The general procedure of Example 6 is repeated using sodium nitrite as an addition reagent, to produce l-nitrosobicyclo[l .l .l]pentane.
  • Example 1 the general procedure of Example 1 is followed using the appropriate reagents.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PCT/US2014/069517 2013-12-12 2014-12-10 Bicyclic alkyl compounds and synthesis Ceased WO2015089170A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN201480067673.7A CN105814013A (zh) 2013-12-12 2014-12-10 双环烷基化合物及合成
US15/103,038 US10189780B2 (en) 2013-12-12 2014-12-10 Bicyclic alkyl compounds and synthesis
EP14869147.0A EP3080072A4 (en) 2013-12-12 2014-12-10 Bicyclic alkyl compounds and synthesis
KR1020167016840A KR102380609B1 (ko) 2013-12-12 2014-12-10 바이사이클릭 알킬 화합물 및 합성
CA2932039A CA2932039A1 (en) 2013-12-12 2014-12-10 Bicyclic alkyl compounds and synthesis
JP2016558533A JP6542794B2 (ja) 2013-12-12 2014-12-10 二環式アルキル化合物、および合成

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361915415P 2013-12-12 2013-12-12
US61/915,415 2013-12-12
US201461949619P 2014-03-07 2014-03-07
US61/949,619 2014-03-07

Publications (1)

Publication Number Publication Date
WO2015089170A1 true WO2015089170A1 (en) 2015-06-18

Family

ID=53371797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/069517 Ceased WO2015089170A1 (en) 2013-12-12 2014-12-10 Bicyclic alkyl compounds and synthesis

Country Status (8)

Country Link
US (1) US10189780B2 (enExample)
EP (1) EP3080072A4 (enExample)
JP (1) JP6542794B2 (enExample)
KR (1) KR102380609B1 (enExample)
CN (2) CN108947867A (enExample)
CA (1) CA2932039A1 (enExample)
TW (1) TWI645901B (enExample)
WO (1) WO2015089170A1 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9693975B2 (en) 2013-03-14 2017-07-04 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
US10189780B2 (en) 2013-12-12 2019-01-29 Zeno Royalties & Milestones, LLC Bicyclic alkyl compounds and synthesis
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
US10793504B2 (en) 2016-08-23 2020-10-06 Recurium Ip Holdings, Llc Methods for cross coupling
WO2020252661A1 (zh) 2019-06-18 2020-12-24 吉林凯莱英医药化学有限公司 螺浆烷类化合物连续合成的方法
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
US11339103B2 (en) 2017-09-11 2022-05-24 Recurium Ip Holdings, Llc Continuous flow processes for making bicyclic compounds
US11655237B2 (en) 2020-03-30 2023-05-23 Gilead Sciences, Inc. Solid forms of a Cot inhibitor compound
US11827662B2 (en) 2019-06-14 2023-11-28 Gilead Sciences, Inc. Cot modulators and methods of use thereof
US11845737B2 (en) 2020-04-02 2023-12-19 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
US11905299B2 (en) 2015-07-06 2024-02-20 Gilead Sciences, Inc. Cot modulators and methods of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102638594B1 (ko) * 2022-05-30 2024-02-19 경희대학교 산학협력단 신규한 바이사이클로펜테인 화합물 및 그의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5404550A (en) * 1991-07-25 1995-04-04 Tandem Computers Incorporated Method and apparatus for executing tasks by following a linked list of memory packets
EP1323725A1 (de) 2001-12-28 2003-07-02 Basf Aktiengesellschaft Verfahren zur Herstellung von 1-Methoxy-2-propanol
US20120270893A1 (en) 2011-04-22 2012-10-25 Pfizer Inc. Substituted acetyl-coa carboxylase inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL54795A (en) 1978-05-26 1980-10-26 Yeda Res & Dev Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
WO1989012085A1 (en) 1988-06-03 1989-12-14 The University Of Texas System Compounds and methods based on [1.1.1]propellane
EP0447484A1 (en) 1988-12-06 1991-09-25 The Upjohn Company Antibacterial quinolone compounds
US5262417A (en) 1988-12-06 1993-11-16 The Upjohn Company Antibacterial quinolone compounds
AU626949B2 (en) 1988-12-06 1992-08-13 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
DE69919142T2 (de) 1998-03-17 2005-01-20 Pfizer Products Inc., Groton Bicyclo [2.2.1] heptane und verwandte verbindungen
WO2000056318A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of neuropathic pain or fibromyalgia
DE10025946A1 (de) 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
US20060052370A1 (en) 2004-08-24 2006-03-09 Meyerson Laurence R Methods and compositions for treating nociceptive pain
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
JP2008120797A (ja) 2006-10-19 2008-05-29 Dainippon Sumitomo Pharma Co Ltd N−置換フェニルアセトアミド誘導体からなる医薬
HRP20100705T1 (hr) 2006-12-27 2011-01-31 Sanofi-Aventis Cikloalkilaminski supstituirani izokinolinski i izokinolinonski derivati
CU20090141A7 (es) 2007-02-06 2011-04-26 Pfizer Compuestos 2-amino pirimidina
WO2009046025A1 (en) 2007-10-01 2009-04-09 Comentis, Inc. Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
AU2010295481A1 (en) 2009-09-18 2012-03-08 Zalicus Pharmaceuticals Ltd. Aryl sulphone derivatives as calcium channel blockers
CA2804147A1 (en) 2010-06-30 2012-01-05 Upsher-Smith Laboratories, Inc. Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid
MX2013003913A (es) 2010-10-08 2013-09-26 Abbvie Inc Compuestos de furo [3, 2-d] pirimidina.
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為mPGES-1抑制物的三環化合物
AP2013007159A0 (en) 2011-04-05 2013-10-31 Pfizer Ltd Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
PE20140502A1 (es) 2011-04-22 2014-05-02 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
AU2012295802B2 (en) 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
EP3321257A1 (en) 2012-02-23 2018-05-16 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
TW201350108A (zh) 2012-04-27 2013-12-16 Nippon Zoki Pharmaceutical Co 鎭痛劑
JP6506248B2 (ja) 2013-03-14 2019-04-24 ゾーン・ロイヤリティズ・アンド・マイルストーンズ・エルエルシー 二環式鎮痛化合物
US20160076098A1 (en) 2013-04-12 2016-03-17 Drexel University Methods of diagnosing and treating chronic pain
ES2663788T3 (es) 2013-06-28 2018-04-17 Evotec International Gmbh Quinazolinas sustituidas con sulfoximina y su uso como inhibidores de MNK1 y/o MNK2 quinasas
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
BR112016002638A2 (pt) 2013-08-12 2017-08-01 Hoffmann La Roche novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
TR201911140T4 (tr) 2013-10-21 2019-08-21 Merck Patent Gmbh Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları.
CN103588668A (zh) 2013-10-28 2014-02-19 史克勇 化合物
CN103588672A (zh) 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物
KR102380609B1 (ko) 2013-12-12 2022-03-30 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 알킬 화합물 및 합성
TW201609671A (zh) 2013-12-20 2016-03-16 標誌製藥公司 經取代之二胺基嘧啶基化合物、其組合物及使用其之治療方法
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
US9603850B2 (en) 2014-04-11 2017-03-28 The University Of North Carolina At Chapel Hill MerTK-specific pyrazolopyrimidine compounds
EP3131891A1 (en) 2014-04-15 2017-02-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
BR112017002001B1 (pt) 2014-07-31 2022-10-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compostos e composição farmacêutica
KR20170048588A (ko) 2014-09-17 2017-05-08 카리라 파마슈티컬스, 아이앤씨. 바이사이클릭 화합물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5404550A (en) * 1991-07-25 1995-04-04 Tandem Computers Incorporated Method and apparatus for executing tasks by following a linked list of memory packets
EP1323725A1 (de) 2001-12-28 2003-07-02 Basf Aktiengesellschaft Verfahren zur Herstellung von 1-Methoxy-2-propanol
US20120270893A1 (en) 2011-04-22 2012-10-25 Pfizer Inc. Substituted acetyl-coa carboxylase inhibitors

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
ANDREW STREITWIESERCLAYTON HEATHCOCK: "Introduction to Organic Chemistry", 1981, pages: 169 - 171
BUNKER ET AL., ORG. LETT., vol. 13, 2011, pages 4746 - 4748
BUNKER, KD ET AL.: "Scalable Synthesis of 1-Bicyclo[1.1.1]pentylamine via a Hydrohydrazination Reaction'.", ORGANIC LETTERS, vol. 13, no. 17, 2011, pages 4746 - 4748, XP055222849 *
FRANCIS CAREY: "Organic Chemistry", 2000, article "John McMurry", pages: 398,408 - 331
GASPAR ET AL., AM. CHEM. SOC., vol. 131, 2009, pages 13214 - 13215
GASPAR ET AL., ANGEW. CHEM., INT. ED., vol. 46, 2007, pages 4519 - 4522
GASPAR ET AL., ANGEW. CHEM., INT. ED., vol. 47, 2008, pages 5758 - 5760
GASPAR, B ET AL.: "ABSTRACT-'Cobalt Catalyzed Functionalization of Unactivated Alkenes: Regioselective Reductive C-C Bond Forming Reactions'.", J. AM. CHEM. SOC., vol. 131, 2009, pages 13214 - 13215, XP055349031 *
GOH, Y. L. ET AL., ORGANIC LETTERS, vol. 16, no. 7, 2014, pages 1884 - 1887
HARVEY ET AL., J. AM. CHEM. SOC., vol. 79, 1957, pages 1437 - 1439
JERRY MARCH: "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", January 2007, WILEY, JOHN & SONS, INC.
KEINAN ET AL., J. ORG. CHEM., vol. 52, 1987, pages 2576 - 2580
LEVIN ET AL., CHEM. REV., vol. 100, 2000, pages 169 - 234
LEVIN, MD ET AL.: "Bicyclo[1.1.1]pentanes, [1.1.1]Propellanes, and Tricyclo[2.1.0.0]pentanes'.", CHEM. REV., vol. 100, 2000, pages 169 - 234, XP055222846 *
LYNCH ET AL., ORG. SYNTH., vol. 75, 1998, pages 98 - 105
RICHARD C. LAROCK: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", November 1999, WILEY, JOHN & SONS, INC.
SCHAUS ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 1307 - 1315
See also references of EP3080072A4
SEMMLER ET AL., J. AM. CHEM. SOC., vol. 107, 1985, pages 6410 - 11
SHTAREV ET AL., J. AM. CHEM. SOC., vol. 123, 2001, pages 3484 - 3492
WASER ET AL., J. AM. CHEM. SOC., vol. 128, 2006, pages 11693 - 11712
WASER, J ET AL.: "Hydrazines and Azides via the Metal-Catalyzed Hydrohydrazination and Hydroazidation of Olefins'.", J. AM. CHEM. SOC., vol. 126, 2006, pages 11693 - 11712, XP055349029 *
WIBERG ET AL., J. AM. CHEM. SOC., vol. 104, 1982, pages 5239 - 40
WIBERG ET AL., TETRAHEDRON LETT, 1964, pages 531 - 4

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724316B2 (en) 2013-03-14 2017-08-08 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
US10251851B2 (en) 2013-03-14 2019-04-09 Zeno Royalties & Milestones, LLC Bicyclic analgesic compounds
US9693975B2 (en) 2013-03-14 2017-07-04 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
US10189780B2 (en) 2013-12-12 2019-01-29 Zeno Royalties & Milestones, LLC Bicyclic alkyl compounds and synthesis
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
US10975035B2 (en) 2014-09-17 2021-04-13 Recurium Ip Holdings, Llc Bicyclic compounds
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
US11905299B2 (en) 2015-07-06 2024-02-20 Gilead Sciences, Inc. Cot modulators and methods of use thereof
US10793504B2 (en) 2016-08-23 2020-10-06 Recurium Ip Holdings, Llc Methods for cross coupling
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
US11339103B2 (en) 2017-09-11 2022-05-24 Recurium Ip Holdings, Llc Continuous flow processes for making bicyclic compounds
US11827662B2 (en) 2019-06-14 2023-11-28 Gilead Sciences, Inc. Cot modulators and methods of use thereof
US12398160B2 (en) 2019-06-14 2025-08-26 Gilead Sciences, Inc. Cot modulators and methods of use thereof
WO2020252661A1 (zh) 2019-06-18 2020-12-24 吉林凯莱英医药化学有限公司 螺浆烷类化合物连续合成的方法
US11655237B2 (en) 2020-03-30 2023-05-23 Gilead Sciences, Inc. Solid forms of a Cot inhibitor compound
US12486252B2 (en) 2020-03-30 2025-12-02 Gilead Sciences, Inc. Solid forms of a Cot inhibitor compound
US11845737B2 (en) 2020-04-02 2023-12-19 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
US12365666B2 (en) 2020-04-02 2025-07-22 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound

Also Published As

Publication number Publication date
US10189780B2 (en) 2019-01-29
CN105814013A (zh) 2016-07-27
CA2932039A1 (en) 2015-06-18
KR102380609B1 (ko) 2022-03-30
EP3080072A4 (en) 2017-07-19
KR20160097230A (ko) 2016-08-17
EP3080072A1 (en) 2016-10-19
CN108947867A (zh) 2018-12-07
JP2017501218A (ja) 2017-01-12
JP6542794B2 (ja) 2019-07-10
US20160311766A1 (en) 2016-10-27
TWI645901B (zh) 2019-01-01
TW201529163A (zh) 2015-08-01

Similar Documents

Publication Publication Date Title
WO2015089170A1 (en) Bicyclic alkyl compounds and synthesis
EP3114107B1 (en) Propellane derivates and synthesis
Gunter et al. Self-assembling porphyrin [2]-catenanes
KR20180038460A (ko) 세포독성 벤조다이아제핀 유도체의 제조 방법
Glenny et al. Improved synthetic methods to mixed-donor thiacrown ethers
KR20210099010A (ko) 세포독성 벤조디아제핀 유도체의 제조 방법
HK1232518B (en) Propellane derivates and synthesis
CN111943893B (zh) 4,7-二氮杂螺[2,5]辛烷类化合物的合成方法
WO2025240628A1 (en) Processes for preparing a pkc inhibitor
Zhang et al. Facile Synthesis of Unsubstituted#,##-Linked Diformyldipyrromethanes
Winstead et al. 1-(6-Ethoxy-6-oxohexyl)-4-methylquinolinium Iodide
JP3845719B2 (ja) メソ−置換ポルフイリン誘導体化合物の製造方法
Surikov et al. Properties of 3, 3-dialkyl-3, 4-dihydro-isoquinoline cyclic azomethines.
KR20250172046A (ko) 브뢴스테드 염기를 이용한 알킬 설포닐 플루오라이드 화합물의 합성방법 및 이를 통해 합성한 알킬 설포닐 플루오라이드 화합물
Brown Synthesis, Structure and Functionalisation of 1, 2-diazetidines
Husain Spatially Directional Resorcin [4] arene Cavitand Glycoconjugates for Organic Catalysis in Aqueous Media
Moradgholi et al. Simple and novel synthetic method to mixed-donor podand
Linton Recognition of molecular anions by design and combinatorial synthesis
Sugihara et al. REACTION OF 1, 2, 3-OXADIAZOLE 3-OXIDES
Kim Corrole Synthesis and Catalytic Applications Toward Cobalt (III)-Catalyzed Epoxidation, NH Insertion, and Cyclopropanation
WO2015031562A1 (en) PROCESS FOR THE PREPARATION OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1H-PYRAZOL-3-YLAMINO)-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO[4,5-d]PYRROLO[2,3-b]PYRIDINE-7-CARBOXAMIDE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14869147

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2932039

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2014869147

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014869147

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15103038

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016558533

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20167016840

Country of ref document: KR

Kind code of ref document: A